Amyris, a US leading synthetic biotechnology company in Clean Health and Beauty markets, launched Terasana Clinical, a clean skin care brand. The launch represents the first of three the company has prepared this summer. Terasana Clinical’s first skincare product, Clear + Control Healthy Skin Serum – the company claims – addresses dry skin, flaking, irritation and redness with its moisturizing and anti-inflammatory properties which are designed to clear and balance the skin’s appearance.
Amyris, a leading synthetic biotechnology company headquartered in the United States of America, executed a binding term sheet for the acquisition of Gen Z-focused beauty brand, EcoFabulous Cosmetics. The acquisition furthers Amyris’s growth and market leadership in clean beauty and complements Amyris’s family of consumer brands, consisting of Biossance®, Pipette®, Rose Inc., JVN, Terasana, and Costa Brazil.
Amyris, a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, successfully scaled up the commercial production of Cannabigerol (CBG) leveraging its industrial fermentation process capability.
Amyris, Inc., a leading synthetic biotechnology company in Clean Health and Beauty markets and IDRI (Infectious Disease Research Institute) signed a binding term sheet for a planned COVID-19 RNA (ribonucleic acid) vaccine technology program. The program combines IDRI’s expertise in combating infectious diseases with Amyris’ fermentation platform technology, with the goal to create semi-synthetic squalene-based adjuvants at scale.
Amyris, Inc., a leading synthetic biotechnology company based in Emeryville (California), launched “Baby Cream to Powder” under its Pipette™ baby brand giving caring parents more choice and keeping babies safe. This safe, talc-free alternative to baby powder goes on as an easy-to-apply cream to prevent and treat diaper rash and irritation and transforms into a silky powder on skin, eliminating the risk of powder inhalation. The announcement by Amyris comes on the heels of news that the largest and leading provider of baby care products will stop selling talcum-based baby powder in the U.S. and Canada amidst questions about its product safety.
Amyris, Inc., a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, successfully shipped the first cannabinoid to its partner, LAVVAN. Amyris is also well on its way to the shipment of a second cannabinoid in the first half of 2020.
Amyris Inc., the US company which develops and produces sustainable ingredients for the Flavors & Fragrances, Health & Wellness and Clean Beauty markets, launched Pipette, a new brand reinventing clean personal care for babies and moms using the fewest possible ingredients from the purest sources.
Amyris, a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, sold its Vitamin E royalty agreement to Koninklijke DSM N.V. (Royal DSM). This agreement assigns Amyris’s rights to Vitamin E royalties to DSM in exchange for total consideration of approximately $57 million. In addition, DSM and Amyris have agreed to a further manufacturing cooperation for Amyris products at DSM’s Brotas facility that provides additional capacity and lower cost of goods sold with an expected approximate aggregate benefit of $30–$40 million over the next three years. The expected economic benefit of both agreements to Amyris is approximately $90 million.
Amyris, Inc., a California-based leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, signed a binding term sheet for a planned cannabinoid development, licensing and commercialization partnership valued at up to $255 million (not including significant royalties once the products are commercialized) with a confidential partner. The $255 million in payments include an upfront payment and the remainder are linked to milestones that are expected over the next 12-36 months following the signing of a definitive final agreement.
Amyris, Inc., the U.S. industrial bioscience company, and Chevron Products Company, a division of Chevron U.S.A. Inc., announced that Novvi LLC and Chevron have entered into an agreement to jointly develop and bring to market novel renewable base oil technologies. Terms of the transaction were not disclosed.
IL BIOECONOMISTA 